LivaNova plc (NASDAQ: LIVN) reported Q4 EPS of $1.00, $0.01 better than the analyst estimate of $0.99. Revenue for the quarter came in at $287.6 million versus the consensus estimate of $296.8 million.

“We are encouraged by several trends in our fourth quarter 2019 results, highlighted by strong sales in Advanced Circulatory Support (ACS) and continued stability in our Epilepsy business. These successes were offset by an unexpected component supplier issue for oxygenators and execution challenges in the Rest of World region relating to distribution model changes," said Damien McDonald, Chief Executive Officer of LivaNova. “Our team is focused, and I am confident that the building blocks we have put in place in 2019 will enable us to achieve our financial and operational goals in 2020.”

GUIDANCE:

LivaNova plc sees FY2020 EPS of $3.10-$3.30, versus the consensus of $3.30.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.